Audentes Therapeutics Inc., a clinical stage biotechnology company, plans to sell $150 million of its common shares in an underwritten public offering.

The company also plans to offer the underwriters an option to buy up to an additional $22.5 million of its common shares at the public offering price.

Audentes Therapeutics will issue all of the shares that to be sold in the offering.

BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers, while Wedbush PacGrow is acting as co-manager for the offering.

San Francisco-based Audentes Therapeutics engages in the development and marketing of gene therapy products for patients suffering from diseases caused by single gene defects.